Hemoglobin level and survival in hemodialysis patients with polycystic kidney disease and the role of administered erythropoietin.
Publication/Presentation Date
8-1-2012
Abstract
Interventional trials indicate adverse outcomes when hemoglobin >13 g/dL is targeted in patients with chronic kidney disease (CKD) who receive erythropoiesis-stimulating agents (ESAs). It is not clear whether high-achieved hemoglobin with minimal to no ESA administration as observed in some patients with polycystic kidney disease (PKD) is also associated with poor outcomes. Survival models were examined to assess the association between hemoglobin increments and mortality in a 6-year cohort of 2,402 PKD and 110,875 non-PKD hemodialysis patients across infrequent versus frequent ESA therapy defined as ESA < 25% of cohort time versus otherwise, respectively. Mortality risk was estimated by Cox proportional regression [hazard ratio (HR) and 95% of confidence interval] analysis. Patients with PKD were aged 58 ± 13 years and included 46% women 14% Blacks, respectively. Fully adjusted death HRs of time-averaged hemoglobin increments13.0 g/dL exhibits better survival; this incremental survival gain of higher hemoglobin is not observed in patients with PKD receiving frequent ESA administration, in whom hemoglobin concentration > 13 exhibits increased mortality.
Volume
87
Issue
8
First Page
833
Last Page
836
ISSN
1096-8652
Published In/Presented At
Shah, A., Molnar, M. Z., Lukowsky, L. R., Zaritsky, J. J., Kovesdy, C. P., & Kalantar-Zadeh, K. (2012). Hemoglobin level and survival in hemodialysis patients with polycystic kidney disease and the role of administered erythropoietin. American journal of hematology, 87(8), 833–836. https://doi.org/10.1002/ajh.23255
Disciplines
Medicine and Health Sciences | Pediatrics
PubMedID
22641426
Department(s)
Department of Pediatrics
Document Type
Article